

DAFTAR PUSTAKA

- Abergel RP, Pizzurro D, Meeker CA, Lask G, Matsuoka LY, Minor RR, Chu ML, Uitto J.1995. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. *J Invest Dermatol*; 84 : 384-390.
- Abreu JG, Ketpura NI, Reversade N, De Robertis EM. 2002. Connective-tissue growth factor (CTGF) modulates cell signaling by BMP and TGF-beta. *Nat Cell Biol*; 4: 599-604.
- Adelmann-Grill BC, Hein R, Wach F, Krieg T.1987. Inhibition of fibroblast chemotaxis by recombinant human interferon gamma and interferon alpha. *J Cell Physiol*; 130 : 270-275.
- Akaishi S, Ogawa R, Hyakusoku H. 2008. Keloid and hypertrophic scar : neurogenic inflammation hypotheses. *Med Hypotheses*; 71 : 32-38.
- Akasaka Y, Fujita K, Ishikawa Y, Asuwa N, Inuzuka K, Ishihara M, Ito M, Masuda T, Akishima Y, Zhang L, Ito K, Ishii T. 2001. Detection of apoptosis in keloids and a comparative study on apoptosis between keloids, hypertrophic scars, normal healed flat scars, and dermatofibroma. *Wound Repair Regen*: 9 : 501-506.
- Akino K, Akita S, Yakabe A, Mineda T, Hayashi T, Hirano A. 2008. Human mesenchymal stem cells may be involved in keloid pathogenesis. *Int J Dermatol*; 47 : 1112-1117.

Akintewe T. A.and Alabi G.O.1985. Scleroderma presenting with multiple keloids. *Br Med J. (Clin. Res. Ed.)* 29:448-449.

Alhady S. M. and Sivanantharajah K.1969. Keloids in various races:A review of 175 cases. *Plast Reconstr Surg.* 44:564-566.

Alster T.S. 1994. Improvement of erythematous and hypertrophic scars by the 585-nm flashlamp-pumped pulsed dye laser. *Ann Plast Surg.* 32(2):186-190.

Alster T.S., Williams C.M. 1995.Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. *Lancet.* 345(8959):1198-1200.

Al-Attar A., Mess S., Thomassen J.M.,Kauffman C.L., Davison S.P. 2006. Keloid pathogenesis and treatment. *Plast Reconstr Surg.* 117:286-300.

Anate M. 1991. Skin closure of laparotomy wounds: Absorbable sub-cuticular sutures vs. non-absorbable interrupted sutures. *West Afr J Med.* 10:150-157.

Andriessen M. P., Niessen F. B., Van de Kerkhof P. C., and Schalkwijk J.1998. Hypertrophic scarring is associated with epidermal abnormalities: An immunohistochemical study. *J Pathol.*186:192-200.

Ashcroft K. J., Syed F., Bayat A. 2013. Site specific keloid fibroblast alter the behaviour of normal skin and normal scar fibroblast through paracrine signaling. *Plos One.* 8 (12) : e75600.

- Babu M., Diegelmann R., Oliver N. 1992. Keloid fibroblasts exhibit an altered response to TGF-beta. *J Invest Dermatol.* 99(5):650-655
- Bailey J.N.R., Waite A.E., Clayton W.J., Rustin M.H.A. 2007. Application of topical mitomycin C to the base of shave-removed keloid scars to prevent their recurrence. *Br J Dermatol.* 156:628-686.
- Baum CL, Arpey CJ, 2005. Normal cutaneous wound healing : clinical correlation with cellular and molecular events. *Dermatol Surg* 2005; 31 : 674-686
- Bayat A., McGrouther D.A., Ferguson M.W.J. 2003. Skin scarring. *Br Med J.* 326:88-92.
- Beer TW. 2005. Keloids are not angiogenic lesions. *J Am Acad Dermatol*; 53 : 1097.
- Begum S., Siddiqui B.S., Sultana R., Suria A. 1999. Bioactive cardenolides from the leaves of *Nerium oleander*. *Phytochemistry.* 50 (3):435-438.
- Ben-Porath I., Weinberg R.A. 2005. The signals and pathways activating cellular senescence. *Inter J Biochem Cell Biol.* 37:961-976.
- Berman B., Amini S, Viera M.H., 2009. Keloid and Hypertrophic Scar. <http://emedicine.medscape.com/article/1057599>.
- Berman B., Duncan M.R. 1989. Short-term keloid treatment *in vivo* with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production *in vitro*. *J Am Acad Dermatol.* 21(4):694-702.

Berridge M. V. and Tan A. S.1993. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. *Arch Biochem Biophys* . 303(2):474–482

Bettinger D. A., Yager D. R., Diegelmann R. F., Cohen I. K., 1996. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. *Plast Reconstr Surg*. 98:827-833

Blazvic' T.M., Brajac I.2006. Detective induction of senescence during wound healing is possible mechanism of keloid formation. *Medical Hypotheses*. 66:649-652.

Bloch E. F., Hall M. G. Jr., Denson M. J., Slay-SolomonV. 1984. General immune reactivity in keloid patients. *Plast ReconstrSurg*. 73:448-451

Bock O., Schmid-Ott G., Malewski P., Mrowietz U.2006. Quality of life of patients with keloid and hypertrophic scarring. *Arch Dermatol Res*. 297:433-438.

Boyadjiev C., Popchristova E., Mazgalova J. 1995. Histomorphologic changes in keloids treated with Kenacort. *J Trauma*. 38(2):299-302.

Boyce DE, Ciampolini J, Ruge F, Murison MS, Harding KG. 2001. Inflammatory-cell subpopulations in keloid scars. *Br J Plast Surg*; 54 : 511-566.

Bradner W.T. 2001. Mitomycin C: a clinical update. *Cancer Treatment Reviews*.
27:35-50.

Bran G.M., Goessler U.R., Baftiri A., Hormann K., Riedel F., Sadick H. 2010.
Effect of transforming growth factor-beta1 antisense oligonucleotides on
matrix metalloproteinases and their inhibitors in keloid fibroblasts.
Otolaryngol Head Neck Surg.143(1):66-71.

Bran G.M., Goessler U.R., Schardt C., Hormann K., Riedel F. 2010. Effect of the
abrogation of TGF-beta1 by antisense oligonucleotides on the expression of
TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from
keloid scars. *Int J Mol Med*. 25(6):915-921.

Bran G.M., Sommer U.J., Goessler U.R., Hörmann K., Riedel F., Sadick H. 2010.
TGF-β1 antisense impacts the SMAD signalling system in fibroblasts from
keloid scars. *Anticancer Res*.30(9):3459-3463.

Brent B. 1978. The role of pressure therapy in management of earlobe keloids.
Ann Plast Surg. 1(6):579-581.

Brody G. S.1990. Keloids and hypertrophic scars. *Plast Reconstr Surg*.86:804.

Butler P.D., Longaker M.T., Yang G.P. 2008. Current Progress in Keloid
Research and Treatment. *J Am Coll Surg*. 206:731-741.

Burton J., Lovell C.R. 1998. *Disorder of Connective Tissue*. 6th ed., Vol.3
Blackwell Science Ltd.

Calderon M., Lawrence W. T., Banes A., 1996. Increased Proliferation in keloid
Fibroblast Wounded *in vitro*. *J Surg Res*. 61:343 –347.

Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. 1999. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. *J Biol Chem*; 274 : 30215-30221.

Campisi J., d'Adda di Fagagna F. 2007. Cellular senescence: when bad things happen to good cells. *Mol Cell Biol*. 8:729-740.

Castagnoli C., Peruccio D., Stella M., 1990. The HLA-DR beta16 allotype constitutes a risk factor for hypertrophic scarring. *Hum Immunol*. 29:229-232.

Chen M.A., Davidson T.M. 2005. Scar management: prevention and treatment strategies. *Curr Opin Otolaryngol Head Neck Surg*.13(4):242-247.

Chen Q.M., Bartholomew J.C., Campisi J., Acosta M., Reagan J.D., Ames B.N. 1998. Molecular analysis of H₂O₂ induced senescence-like growth arrest in normal human fibroblast: p53 and Rb control G₁ arrest but not cell replication. *Biochem J*. 332:43-50.

Chen Q.M., Liu J., Merret J.B. 2000. Apoptosis or senescence-like growth arrest: influence of cell-cycle position, p53, p21 and bax in H₂O₂ response of normal human fibroblast. *Biochem J*. 543-551.

Chen TC., Lai CH., Chang JL., Chang SW. 2012. Mitomycin C retardation of corneal fibroblast migration via sustained dephosphorylation of paxillin at tyrosine 118. *Invest Ophthalmol Vis Sci*. 53: 1539-1547.

Chipev CC, Simman R, Hatch G, Katz AE, Siegel DM, Simon M. 2000. Myofibroblast phenotype and apoptosis in keloid and palmar fibroblasts in vitro. *Cell Death Differ*; 7 : 166-176.

Christophers E. 1974. Growth stimulation of cultured postembryonic epidermal cells by vitamin A acid. *Journal of Investigative Dermatology* . 63; 450–455.

Chytilova M., Kulhanek V., and Horn V. 1960. Keloids as a form of auto-aggression in the scar. *Rozhl Chir*. 39:393-399.

Caulfield RH, Tyler MP, Austyn JM, Dziewulski P, McGrouther DA. 2008. The relationship between protease/antiprotease profile, angiogenesis and re-epithelialisation in acute burn wounds. *Burns*; 34 : 474-486.

Clayman M.A., Clayman S.M., Mazingo D.W. 2006. The use of collagen-glycosaminoglycan copolymer (Integra) for the repair of hypertrophic scars and keloids. *J Burn Care Res*. 27(3):404-409.

Clugston P.A., Vistnes M.D., Perry L.C., Maxwell G.P., Fisher J. 1995. Evaluation of silicone-gel sheeting on early wound healing of linear incisions. *Ann Plast Surg*. 34(1):12-15.

Cohen I. K., McCoy B. J., Mohanakumar T., and Diegelmann R. F. 1979. Immunoglobulin, complement, and histocompatibility antigen studies in keloid patients. *Plast Reconstr Surg*. 63:689-695.

Conejo-Mir J.S., Corbi R., Linares M. 1998. Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids. *J Am Acad Dermatol*. 39(6):1039-1040.

Craig R. D. 1975. Collagen biosynthesis in normal human skin, normal and hypertrophic scar and keloid. *Eur J Clin Invest*. 5:69-74.

- Cristofalo V.J., Lorenzini A., Allen R.G., Torres C., Tresini M. 2004. Replicative senescence: a critical review. *Mechan Aging Dev.* 125:827-848.
- Curth W., and McSorley J. 1971. Multiple keloids. *Arch Dermatol.* 104:106-107.
- Curtis A. S., and Seechar G. M. 1978. The control of cell division by tension or diffusion. *Nature.* 274: 52-53.
- Darby IA, Laverdet B, Bonté F, Desmoulière A. 2014. Fibroblasts and myofibroblasts in wound healing. *Dovepress.* 7: 301-311.
- Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. 1993. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. *J Cell Biol*; 122 : 103-111.
- Devon, T. K., and Scott, A. I., 1972, *Handbook of Naturally Occurring Compounds*, volume II, p.422, Terpenes, Academic Press, New York.
- Diegelmann R. F., Bryant C. P., and Cohen I. K. 1977. Tissue alpha-globulins in keloid formation. *Plast Reconstr Surg.* 59:418-423.
- Dimri G.P., Lee X., Basile G., Acosta M., Scott M., Roskelley C., Medrano E.E., Linskens M., Rubeli I., Pereira-Smith O. 1995. A biomarker that identifies senescent human cells in culture and aging skin *in vivo*. *Proc Natl Acad Sci U. S. A.* 92:9363-9367.
- Dovi JH, He LK, DiPietro LA. 2003. Accelerated wound closure in neutrophil-depleted mice. *J Leukoc Biol*; 73 : 448-455.
- Dumont P., Burton M., Chen Q.M., Gonos E.S., Fripiat C., Mazarati J.B., Eliaers F., Remacle J., Toussaint O. 2000. Induction of replicative senescence

biomarkers by sublethal oxidative stresses in normal human fibroblast.

Free Rad Biol Med. 28:361-373.

Dunkin CS, Pleat JM, Gillespie PH, Tyler MP, Roberts AH, McGrouther DA.

2007. Scarring occurs at a critical depth of skin injury : precise measurement in a graduated dermal scratch in human volunteers. *Plast Reconstr Surg.* 119 : 1722-1732.

Dunn D. E., He D. N., Yang P., Johansen M., Newman R. A., Lo D. C.2011. *In vitro* and *in vivo* neuroprotective activity of the cardiac glycoside oleandrin from *Nerium oleander* brain slice-based stroke models. *J Neurochem.*119:805–814.

D’Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Flegler L., Flegler H., Carr P., von Zglinicki T., Saretzki G., Carter N.P., Jackson S.P. 2003. A DNA damage checkpoint response in telomereinitiated senescence. *Nature* . 426: 194-198.

D’Andrea F., Brongo S., Ferraro G., Baroni A. 2002. Prevention and treatment of keloids with intralesional verapamil. *Dermatology*; 204(1):60-62.

Elmora S.2007. Apoptosis: A Review of Programmed Cell Death. *Toxicol Pathol.* 35:495-516.

English RS, Shenefelt PD. 1999. Keloids and hypertrophic scars. *Dermatol Surg.* 25 : 631-638.

Espinassouze F., Heid E., Grosshans E. 1993. Treatment of keloid by intralesional injections of interferon alpha-2 b. *Ann Dermatol Venereol.* 120 : 629-630.

Estrem S. A., Domayer M., Bardach J., and Cram, A. E. 1987. Implantation of human keloid into athymic mice. *Laryngoscope*. 97:1214-1218.

Fasika O.M. 1992. Keloids: A study of the immune reaction to sebum. *East Afr Med J*. 69: 114.

Felth J., Rickardson L., Rosén J., Wickström M., Fryknäs M. 2009. Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. *J Nat Prod*. 72(11):1969-1974.

Fitzpatrick R. E. 1999. Treatment of Inflamed Hypertrophic Scars Using Intralesional 5-FU. *Dermatol Surg*. 25(3):224-232.

Fong E. P., and Bay B. H. 2002. Keloids: The sebum hypothesis revisited. *Med Hypotheses*. 58:264-269.

Fong E. P., Chye L. T., and Tan W. T. 1999. Keloids: Time to dispel the myths? *Plast Reconstr Surg*. 104:1199-1201.

Frantz FW, Bettinger DA, Haynes JH, Johnson DE, Harvey KM, Dalton HP, Yager DR, Diegelmann RF, Cohen IK. 1993. Biology of fetal repair : the presence of bacteria in fetal wounds induces an adult-like healing response. *J Pediatr Surg*; 28 : 428-433

Friedman D. W., Boyd C. D., Mackenzie J. W., Norton P., Olson R. M., and Deak S. B. 1993. Regulation of collagen gene expression in keloids and hypertrophic scars. *J Surg Res*. 55:214-222.

Fujiwara M., Muragaki Y., Ooshima A. 2005. Keloid-derived fibroblast show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. *Br J Dermatol*.153(2): 295-300.

Funayama E, Chodon T, Oyama A, Sugihara T. 2003. Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts : an important role in the pathogenesis of keloid. *J Invest Dermatol*. 121 : 1326-1331.

From I.M., Assdad D.1999. New plasma, pseudomonas, and Hyperplasias of the Dermis 5th ed., Vol 1.(F, IM,Ed) New York: Mc-Graw Hill.

Gadson P.F., Russell J.D., Russell S.B. 1984. Glucocorticoid receptors in human fibroblasts derived from normal dermis and keloid tissue. *J Biol Chem*. 259(18):11236-11241.

Gurtner GC, Werner S, Barrandon Y, Longaker MT. 2008. Wound repair and regeneration. *Nature*; 453 : 314-321.

Garner E., Raj K.2008. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. *Cell cycle*. 7: 1-6.

Gira AK, Brown LF, Washington CV, Cohen C, Arbiser JL.2004. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. *J Am Acad Dermatol*; 50 : 850-853.

Gold M.H. 1994. A controlled clinical trial of topical silicone gel sheeting in the treatment of hypertrophic scars and keloids. *J Am Acad Dermatol*. 30(3):506-507.

Golpon H.A., Fadok V.A., Taraseviciene-Stewart L., Scerbavicius R., Sauer C.,

Welte T., Henson P.M., Voekel N.F. 2004. Life after corpse engulfment:
phagocytosis of apoptotic cells leads to VEGF secretion and cell growth.

The FASEB Journal. 18: 1716-1718.

Goodfellow A, Emmerson RW, Calvert HT. 1980. Rubinstein-Taybi syndrome
and spontaneous keloids. *Clin Exp Dermatol*. 5 : 369-370.

Gurtner GC, Wong, VW. 2014. Wound healing: normal and abnormal. *Grabb and
Smith's Plastic surgery seventh edition*. 2:13-19.

Greenhalgh D.G.1998. The role of apoptosis in wound healing.*Inter J Biochem
Cell Biol*. 30:1019-1030.

Grimes P.E., Hunt S.G. 1993. Considerations for cosmetic surgery in the black
population. *Clin Plast Surg*. 20(1):27-34.

Haisa M, Okochi H, Grotendorst GR. Elevated levels of PDGF alpha receptors in
keloid fibroblasts contribute to an enhanced response to PDGF. *J Invest
Dermatol* 1994; 103 : 560-563.

Hambrick G. W., Jr., and Carter D. M. 1966. Pachydermoperiostosis:Touraine-
Solente-Gole syndrome. *Arch Dermatol*. 94:594-608.

Harper RA. 1989. Keloid fibroblasts in culture : abnormal growth behaviour and
altered response to the epidermal growth factor. *Cell Biol Int Rep*; 13 :
325-335.

Hart J. 2002. Inflammation. 1 : its role in the healing of acute wounds. *J Wound
Care*: 11 : 205-209.

Harting M., Hicks J. M., Levy M. 2008. *Dermal Hypertrophies*. In: Wolffk, Goldsmith L. A., Katz S. I., Gilchrest B. A., Paller A. S., Leffell D. J., editor. Fitzpatrick's Dermatology in General Medicine. 7th ed. Mc Graw Hill Companies, Inc. 556-558.

Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, Drew AF. 2000. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. *J Clin Invest*; 106 : 1341-1350.

Hazrati, E., and Hoomand. 1977. A. The keloidal diathesis: A resistant state to malignancies? *Plast Reconstr Surg*. 59: 555-559.

Herbig U., Jobling W.A., Chen B.P.C., Chen D.J., Sedivy JM. 2004. Telomere Shortening Triggers Senescence of Human Cells through a Pathway Involving ATM, p53, and p21^{CIP1}, but Not p16^{INK4a}. *Mol Cell*. 14: 501-513.

Heng E.C., Huang Y., Black Jr., SA., Trackman P.C. 2006. CCN2 connective tissue growth factor, stimulates collagen deposition by gingival fibroblast via module 3 and $\alpha 6$ -and $\beta 1$ integrin. *J Cell Biochem*. 98(2) : 409-420.

Hornebeck W. 2003. Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival. *Pathologie Biologie*. 51: 569-573.

Hubner G, Brauchle M, Smola H, Madlener M, Fassler R, Werner S. 1996. Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. *Cytokine*; 8 : 548-556.

Huntington JA.2005. Molecular recognition mechanism of thrombin. *J Thromb Haemost* ; 3 : 1861-1872.

Hunzelmann N., Anders S., Sollberg S., Schonherr E., and Krieg T.1996. Co-ordinate induction of collagen type I and biglycan expression in keloids. *Br J Dermatol*. 135: 394-399.

Ikawa Y., Ng P.S., Endo K., Kondo M., Chujo S.,Ishida W.,Shirasaki F., Fujimoyo M., Takehara K. 2008. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor beta induced mouse fibrosis. *JCell Physiol*. 216(3):680-687.

Ishihara H, Yoshimoto H, Fujioka M, Murakami R, Hirano A, Fujii T, Ohtsuru A, Namba H, Yamashita S. 2000. Keloid fibroblasts resist ceramid-induced apoptosis by overexpression of insulin-like growth factor I receptor. *J Invest Dermatol*; 115 : 1065-1071.

Jagadeesan J, Bayat A. 2007. Transforming growth factor beta (TGF β) and keloid disease. *Int J Surg*; 5 : 278-285.

Janssen de Limpens A. M. 1980.The local treatment of hypertrophicscars and keloids with topical retinoic acid. *Br J Dermatol*. 103:319-323.

Jimenez SA, Freundlich B, Rosenbloom J. 1984. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. *J Clin Invest*; 74 : 1112-1116.

Jun J., Lau L.F. 2010. Cellular senescence controls fibrosis in wound healing. *Aging* 2: 627-631.

Kazeem A. A.1988.The immunological aspects of keloid tumorformation. *J Surg Oncol.* 38:16-18.

Kelly A.P. 1991. *Keloids and Hipertrophic scars.1st ed.*. New York; McGraw-Hill.Inc.

Kelly A.P. 2004. Medical and surgical therapies for keloids. *Dermatol Therapy.* 17: 212-218.

Khoo YT, Ong CT, Mukhopadhyay A, Han HC, Do DV, Lim IJ, Phan TT.2006. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. *J Cell Physiol*; 208 : 336-343.

Kischer C. W.1993. Contributions of electron microscopy to thestudy of the hypertrophic scar and related lesions. *ScanningMicrosc.* 7: 921-930.

Kischer C. W. 1992. The microvessels in hypertrophic scars, keloidsand related lesions: A review. *J Submicrosc Cytol Pathol.* 24:281-296.

Kischer C. W., Wagner H. N., Jr., Pindur J., Holubec H., Jones M., Ulreich J. B., Scuderi P.1989. Increased fibronectin production by cell lines fromhypertrophic scar and keloid. *Connect Tissue Res.* 23:279-288.

Kleinerman R., Kilmer S.L., Chotzen V.A.2013. Mitomycin C in the treatment of keloids: a case and review. *J Drugs Dermatol.* 12(6):701-703.

Knighton D. R., Hunt T. K., Scheuenstuhl H., Halliday B. J.,Werb Z., and Banda M. J.1983. Oxygen tension regulates the expression of angiogenesis factor by macrophages. *Science.* 221:1283

- Kovalic J.J., Perez C.A. Radiation therapy following keloidectomy: a 20-year experience. 1989. *Int J Radiat Oncol Biol Phys*. 17(1):77-80.
- Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., Yee H., Zender L., Lowe S.W.2008. Senescence of activated stellate cells limits liver fibrosis. *Cell*. 134: 657-667.
- Kumar A., De T., Mishra A., Mishra A.K. 2013. Oleandrin: A cardiac glycosides with potent cytotoxicity.*Pharmacogn Rev*. 7(14):131-139.
- Ladin DA, Hou Z, Patel D, McPhail M, Olson JC, Saed GM, Fivenson DP. p53 and apoptosis alterations in keloids and keloid fibroblasts. *Wound Repair Regen* 1998; 6 : 28-37.
- Lampugnani M.G. 1999.Cell migration into a wounded area in vitro. *Methods Mol Biol*. 96:177-182.
- Larrabee W.F.Jr., East C.A., Jaffe H.S., Stephenson C., Peterson K.E. 1990. Intralesional interferon gamma treatment for keloids and hypertrophic scars. *Arch Otolaryngol Head Neck Surg*. 116(10):1159-1162.
- Laurentaci G., and Dioguardi D.1977.HLA antigens in keloids and hypertrophic scars. *Arch Dermatol*. 113(12): 1726.
- Luo S, Benathan M, Raffoul W, Panizzon RG, Egloff DV.2001. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. *Plast Reconstr Surg*; 107 : 87-96.

Lawrence W.T. 1996. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. *Ann Plast Surg.* 37(2):167–169.

Leake D, Doerr TD, Scott G. 2003. Expression of urokinase-type plasminogen activator and its receptor in keloids. *Arch Otolaryngol Head Neck Surg*; 129 : 1334-1338.

Lee B.Y., Han J.A., Im J.B., Morrone A., Johung K., Goodwin E.C., Kleijer W.J. Di Maio D., Hwang E.S. 2006. Senescence-associated β -galactosidase is lysosomal β -galactosidase. *Aging Cell.* 5:187-195.

Lee J., Jung E., Yu H., Kim Y., Ha J., Kim Y.S., Park D. 2008. Mechanisms of carvacrol-Cell. Binduced expression of type1 collagen gene. *J Dermatol Sci*, 52 (3) : 160-169.

Lee R.C., Ping J.A. 1990. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. *J Surg Res.* 49(5):463-466.

Lee S.S., Yosipovitch G., Chan Y.H., Goh C.L. 2004. Pruritus, pain, and small nerve fiber function in keloids: A controlled study. *JAm Acad Dermatol.*51:1002-1006.

Lee C.H., Hong C.H., Chen Y.T., Chen Y.C., Shen M.R. 2012. TGF-beta1 increases cell rigidity by enhancing expression of smooth muscle actin: keloid-derived fibroblasts as a model for cellular mechanics. *J Dermatol Sci.* 67(3):173-180.

Leibovich SJ, Ross R. 1975. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. *Am J Pathol*; 78 : 71-100.

Liang Y., Niederstrasser H., Edwards M., Jackson C.E., Cooper J.A. 2009. Distinct roles for CARMIL isoforms in cell migration. *Mol Biol Cell*. 20(24):5290-5305.

Lim IJ, Phan TT, Bay BH, Qi R, Huynh H, Tan WT, Lee ST, Longaker MT.2002. Fibroblasts cocultured with keloid-keratinocytes: normal fibroblasts secrete collagen in a keloid-like manner. *Am J Physiol Cell Physiol*; 283 : C212-222.

Lin Y., Ho D.H., Newman R.A.2010. Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na⁺, K⁺ -ATPase subunits. *J Exp Ther Oncol*. 8(4):271-286.

Ludovic M, Nicolas V, Fabricce B, Bernard C, Ian AD, Alexis D., 2010. The myofibroblas, multiple origins for major roles in normal and pathological tissue repair. *Fibrogenesis & Tissue Repair*, 5(Suppl 1):55.

Luo S., Benathan M., Raffoul W., Panizzon R. G., and EgloffD. V. 2001. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. *Plast Reconstr Surg*. 107:87-96.

Machin D., Campbell M., Fayers P., Pinol A. 1997. *Sample Size Tables for clinical Studies*, 2nded. Blackwell Science. 73-74.

Macieira-Coelho A. 1998. Markers of cell senescence. *Mechanism of Ageing and Development*. 103:105-109.

Maneros A.G., Krieg T. 2004. Keloid-clinical, pathogenesis, and treatment options. *J Deutsch Dermatol Gesell.* 2:905-913.

Manna S.K., Sah N.K, Newman R.A.2000. Oleandrin Suppresses Activation of Nuclear Trancription Factor-kB, activator Protein-1, and c-Jun NH₂-Terminal Kinase. *Cancer Res.* 60:3838-3847.

Manna S.K., Sreenivasan Y., Sarkar A.2006. Cardiac glycoside inhibits IL-8-induced biological responses by downregulating IL-8 receptors through altering membrane fluidity. *J Cell Physiol.*207(1):195-207.

Manuskiatti W. 2002. Comparison Among Intralesional Corticosteroid, 5-Fluorouracil, and 585-nm Flashlamp-Pumped Pulsed-Dye Laser Treatments. *Arch Dermatol.* 138:1149-1155.

Marneros AG, Norris JE, Olsen BR, Reichenberger E. 2001. Clinical genetics of familial keloids. *Arch Dermatol*; 137 : 1429-1434.

Marshall N.J., Goodwin C.J., Holt S.J.1995. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. *Growth Regul.*5(2):69–84.

Martin P, D’Souza , Martin J, Grose L, Cooper L, Maki R, McKercher SR. 2003. Wound healing in the PU.1 null mouse-tissue repair is not dependent on inflammatory cells. *Curr Biol*; 13 : 1122-1128.

McCauley RL, Chopra V, Li YY, Herndon DN, Robson MC. 1992. Altered cytokine production in black patients with keloids. *J Clin Immunol*; 12 : 300-308.

Messadi DV, Le A, Berg S, Huang G, Zhuang W, Bertolami CN.1998. Effect of TGF-beta 1 on PDGF receptors expression in human scar fibroblasts. *Front Biosci*; 3 : a16-22.

Milsom J. P., and Craig R. D. 1973. Collagen degradation in cultured keloid and hypertrophic scar tissue. *Br J Dermatol*. 89:635-644.

Moon JH, Kwak SS, Park G, Jung HY, Yoon BS, Park J, Ryu KS, Choi SC, Maeng I, Kim B, Jun EK, Kim S, Kim A, Oh S, Kim H, Kim KD, You S.2008. Isolation and characterization of multipotent human keloid-derived mesenchymal-like stem cells. *Stem Cells Dev*; 17 : 713-724.

Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 65(1-2):55-63.

Moustafa MF, Abdel-Fattah MA, Abdel-Fattah DC. 1975. Presumptive evidence of the effect of pregnancy estrogens on keloid growth. Case report. *Plast Reconstr Surg*; 56 : 450-453.

Mrowietz U., Seifert O.2009. Keloid scarring: new treatments ahead. *Actas Dermosifiliogr*. 2:75-83.

Mukherjee A., Mukherjee A., and Saha K. C.1982. Delayed type hypersensitivity reaction to cutaneous antigen in keloid. *Indian J Dermatol*. 27:125-130.

Murray J. C., Pollack S. V., and Pinnell S. R.1981. Keloids: A review. *J Am Acad Dermatol*. 4:461-470.

Mustoe T.A., Cooter R.D., Gold M.H., Hobbs R., Ramelet A.A., Shakespeare P.G., Stella M., Teot L., Wood F.M., Ziegler U.E. 2002. International

Clinical Recommendations on Scar Managements. *Plast Reconstr Surg.*
110:560-571.

Nasu S., Milas L., Kawabe S., Raju U., Newman R.A. 2002. Enhancement of
radiotherapy by oleandrin is a caspase-3 dependent procces. *Cancer*
Letters.185(2000):145-151.

Newman R.A., Kondo Y., Yokoyama T., Dixon S., Cartwright C. 2007.
Autophagic cell death of human pancreatic tumor cells mediated by
oleandrin, a lipid-soluble cardiac glycoside. *Integr Cancer Ther.* 6(4):354-
364.

Newsome, E. 2009. Wound healing, keloids. Medscape reference. JA Molnar.

Niessen F. B., Spauwen P. H., and Kon M.1997. The role of suturematerial in
hypertrophic scar formation: Monocryl vs. Vicryl-rapide. *Ann Plast Surg.*
39: 254-260.

Niessen F.B., Spauwen P.H , Schalkwijk J., Kon M. 1999. On the nature of
hypertrophic scars and keloids: a review. *Plast Reconstr Surg.*
104(5):1435-1458.

Norris J.E. 1991. Hypertrophic scar and keloid. *Plast Reconstr Surg.* 88(2):372-
373.

Norris JE. 1995. Superficial x-ray therapy in keloid management: a retrospective
study of 24 cases and literature review. *Plast Reconstr Surg.* 95(6):1051-
1055.

- Ogawa R., Mitsuhashi K., Hyakusoku H., and Miyashita T. 2003. Postoperative electron-beamirradiation therapy for keloids and hypertrophic scars: Retrospective study of 147 cases followed formore than 18 months. *Plast Reconstr Surg.* 111:547-553.
- Ogryzko V.V., Liirai T.I., Russanova V.R., Barbie D.A., Howard B.H.1996. Human Fibroblast Commitment to a Senescence-Like State in Response to Histone Deacetylase Inhibitors Is Cell Cycle Dependent. *Mol Cell Biol.* 16:5210-5218.
- O’Kane S. 2002. Wound remodelling and scarring. *J Wound Care*; 11 : 296-299.
- O’Sullivan ST, O’Shaughnessy M, O’Connor TP. 1996. Aetiology and management of hypertrophic scars and keloids. *Ann R Coll Surg Engl.* 78 (Part I) : 168-175.
- Pathak S., Multani A.S., Narayan, Kumar V., Newman R.A. 2000. Anvirzel, an extract of *Nerium oleander* induces cell death in human, but not murine cancer cell. *Anti cancer drugs.* 11(6):455-463.
- Park G., Yoon, B. S., Moon, J.H., Kim B., Jun E. K. , Sejong, K. H., Song H. J., Noh, J. Y., Chill H., Sungkwonn Y. 2008. Green Tea Polyphenol Epigallocatechin-3-Gallate Suppresses Collagen Production and Proliferation in Keloid Fibroblasts via Inhibition of the STAT3-Signaling Pathway. *J Invest Dermatol.* 128:2429-2441.
- Peacock E.E.Jr., Madden J.W., Trier W.C.1970. Biologic basis for the treatment of keloids and hypertrophic scars. *South Med J.* 63(7):755-760.

Peacock E. E., Jr. 1981. Pharmacologic control of surface scarring in human beings. *Ann Surg.* 193:592.

Pearlstein E., Gold L. I., Garcia-Pardo A. 1980.Fibronectin: A review of its structure and biological activity. *Mol Cell Biochem.* 29:103-128.

Pelicci P.G. 2004. Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? *JClin Invest.* 113:4-7.

Peltonen J., Hsiao L.L., Jaakkola S., Sollberg S., Aumailley M.1991.Activation of collagen gene expression in keloids: co-localization of type I and VI collagen and transforming growth factor-beta 1 mRNA. *J Invest Dermatol.*97(2):240-248.

Peltonen J., Hsiao L.L., Jaakkola S., Sollberg S., Aumailley M., Timpi R. 1991. Activation of Collagen Gene Expression in Keloid : Co-Localization of Type I and VI Collagen and Transforming Growth Factor – β 1 mRNA. *J Invest Dermatol.* 97 : 240 – 248.

Perdanakusuma D.S. dan Noer M.S. 2006. Penanganan parut hipertrofik dan keloid. *Airlangga University Press.*

Pierce G. F., Tarpley J. E., Yanagihara D., Mustoe T. A., Fox G. M., Thomason, A.1992. Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing: Neovessel and matrix formation and cessation of repair. *Am J Pathol.* 140:1375-1388.

Placik O. J., Lewis V. L., Jr. 1992.Immunologic associations ofkeloids. *Surg Gynecol Obstet.* 175:185-193.

Poochaeron V.N. and Berman B.2003. New therapies for the management of keloid. *J Craniofac Surg.* 14:654–657.

Prasetyawati C. 2004.Uji sitotoksitas sub kronis infusa daun *Nerium indicum* Mill. pada tikus putih jantan (*Rattus norvegicus*) galur wistar.*Indonesian J Pharm.* 15(1):13-19.

Quinn K.J., Evans J.H., Courtney J.M., Gaylor J.D., Reid W.H. 1985. Non-pressure treatment of hypertrophic scars. *Burns Incl Therm Inj.* 12(2):102-108.

Ragoowansi R., Cornes P.G., Moss A.L., Glees J.P. 2003. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. *Plast Reconstr Surg.* 111(6):1853-1859.

Ramakrishnan K. M., Thomas K. P.,Sundararajan C. R.1974. Study of 1,000 patients with keloids in South India. *Plast Reconstr Surg.* 53:276-280,.

Reiffel R. S.1995. Prevention of hypertrophic scars by long-term paper tape application. *Plast Reconstr Surg.* 96:1715-1718.

Robles DT, Berg D. 2007. Abnormal wound healing : keloids. *Clin Dermatol.* 25 : 26-32.

Robles S.J., Adami G.R., 1998. Agents that cause DNA double strand breaks lead to p16^{INK4a} enrichment and the premature senescence of normal fibroblast. *Oncogen.* 16:1113-1123.

Russell S. B., Trupin K. M., Rodriguez-Eaton S., Russell J. D., Trupin J. S.1998. Reduced growth-factor requirement of keloid-derived fibroblasts may account for tumor growth. *Proc Natl Acad Sci U. S. A.* 85:587-591.

Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. 2007.

Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF) – beta1-induced collagen synthesis. *Wound Repair Regen.* 15 : 122-133.

Satish L., Babu M., Tran, Kien T., Hebda, Patricia A., Wells, A. 2003. Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signalling pathways. *Wound Rep Reg.* 12:183-192.

Sayah D.N., Soo C., Shaw W. W., Watson J., Messadi D., Longaker M.T., Zhang X., Ting K. 1999. Downregulation of Apoptosis–Related Genes in Keloid Tissues. *J Surg Res.* 87:209 – 216.

Schafer M, Werner S. 2008. Cancer as an overhealing wound : an old hypothesis revisited. *Nat Rev Mol Cell Biol;* 9 : 628-638.

Schoner W., and Scheiner-Bobis G.2007. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth.*Am J Physiol Cell Physiol.*293(2):C509-536

Scott I.U., Greenfield D.S., Schiffman J., Nicolela M.T., Rueda J.C., Tsai J.C., Palmberg P.F.1998. Outcome of primary trabeculectomy with the use of adjunctive mitomycin.*Arch Ophthalmol.* 116:286-291.

Seifert O., Mrowietz U. 2009. Keloid scarring: bench and bedside. *Arch Dermatol Res.* 301:259-272.

Seo S.H., Sung H.W. 2012. Treatment of keloids and hypertrophic scars using topical and intralesional mitomycin C. *J Eur Acad Dermatol Venereol*. 26 (5): 634-638.

Serrano M., Lin A. W., McCurrach M.e., Beach D., Lowe S.W.1997. Oncogenic *ras* provokes premature cell senescence associated with accumulation of p53 and p16^{INK4a}. *Cell*. 88:593-602.

Shah M, Foreman DM, Ferguson MW. 1995. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. *J Cell Sci*; 108 (Part 3) : 985-1002.

Shapiro P.E.1997.*Hipertrophic scar and Keloid*(6th ed). Philadelphia, New York: Lipponcote-Ravem Publ.

Shejbal D., Bedeković V., Lvkic M., Kalogjera L., Aleric Z., Drviš P. 2004. Strategies in the treatment of keloid and hypertrophic scarr. *Acta Clinica Croatia*. 43:417-422.

Shetlar M. R., Shetlar C. L., Hendricks L., and Kischer C. W. 1985. The use of athymic nude mice for the study of human keloids.*Proc Soc Exp Biol Med*. 179:549-552.

Shi C.M, Cheng T.M., Su Y.P. 2004. Effect of dermal multipotent cell transplantation on skin wound healing. *J Surg Res*. 121(1):13-19.

Shih B, Garside E, McGrouther DA, Bayat A. 2010. Molecular dissection of abnormal wound healing processes resulting in keloid disease. *Wound Rep Reg*.18:139–153

- Sible J.C., Eriksson E., Oliver N. 1996. DNA binding proteins from keloid fibroblasts form unique complexes with the human fibronectin promoter. *Gene Expr.* 5(6):269-283.
- Siraganian P. A., Rubinstein J.H., Miller R.W. 1989. Keloids and neoplasms in the Rubinstein-Taybi syndrome. *Med Pediatr Oncol.* 17:485-491.
- Simman R., Alani H., Williams F. 2003. Effect of mitomycin C on keloid fibroblast: An *in vitro* study. *Ann Plast Surg.* 50:71-76.
- Smith P., Mosiello G., Deluca L., Ko F., Maggi S., Robson M.C. 1999. TGF-beta2 activates proliferative scar fibroblasts. *J Surg Res.* 82(2):319-323.
- Smith C. J., Smith J. C., Finn M. C. 1987. The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. *J Burn Care Rehabil.* 8:126-131.
- Smith J.A., Madden J., Vijjeswarapu M., Newman R.A. 2001. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell line PC₃ and DU 145 by Anvirzel and its cardiac glycoside component, oleandrin. *Biochem Pharmacol.* 62(2001): 469-472.
- Smith JC, Boone BE, Opalenik SR, Williams SM, Russel SB. 2008. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. *J Invest Dermatol*; 128 : 1298-1310.
- Sollberg S., Peltonen J., Uitto J. 1991. Combined use of *in situ* hybridization and unlabeled antibody peroxidase anti-peroxidase methods: Simultaneous detection of type I procollagen mRNAs and factor VIII-related antigen epitopes in keloid tissue. *Lab Invest.* 64:125-129.

Song J., Xu H., Lu Q., Xu Z., Bian D., Xia Y., Wei Z., Gong Z., Dai Y. 2012.

Madecassoside suppresses migration of fibroblast from keloids:
involvement of p38 kinase and P13K. *Burns*. 38(5):677-684.

Sproat JE, Dalcin A, Weitauer N, Roberts RS. 1992. Hypertrophic sternal
scars: silicone gel sheet vs Kenalog injection treatment. *Plast Reconstr
Surg*;90(6): 988-992.

Sreenivasan Y., Sarkar A., Manna S.K. 2003. Oleandrin suppress activation of
nuclear transcription factor-kappaB and activator protein-1 potentiates
apoptosis induced by ceramide. *Biochem Pharmacol*.66(11):223-239.

Stewart C.E., Kim J.Y., Linda I. 2006. Application of mitomycin-C for head and
neck keloids. *OtolaryngolHead Neck Surg*. 135: 946-950.

Strauss J. S.1959. Radiation therapy of acne. *ConnMed*. 23:654-655.

Subramanian R, White CJ, Sternbergh WC 3rd, Ferguson DL, Gilchrist IC. 2003.
Nonhealing wound resulting from a foreign-body reaction to a radial
arterial sheath. *Catheter Cardiovasc Interv*; 59 : 205-206.

Sussman M. D.1966. Effect of increased tissue traction upon tensile strength of
cutaneous incisions in rats. *Proc Soc Exp Biol Med*.123:38-41.

Syed F., Ahmadi E., Iqbal S.A., Singh S., McGrouther D.A., Bayat A. 2011.
Fibroblast from the rowing margin of keloid scars produce higher levels of
collagen I and III compared with intralesional and extralesional sites:
clinical implications for lesional site-directed therapy. *Br J Dermatol*. 164
(1): 83-96.

Talmi Y.P., Orenstein A., Wolf M., Kronenberg J. 2005. Use of mitomycin C for treatment of keloid: a preliminary report. *Otolaryngol Head Neck Surg.* 132(4):598-601.

Taskiran D., Taskiran E., Yercan H., Kutay F.Z. 1999. Quantification of total collagen in rabbit tendon by the Sirius Red Methods. *TrJMed Sci.* 29:7 – 9.

Teelucksingh S, Balkaran B., Ganeshmoorthi A., Arthur P. 2002. Prolonged childhood Cushing's syndrome secondary to intralesional triamcinolone acetonide. *Ann Trop Paediatr.* 22(1):89-91.

Toriseva M, Kahari VM. 2009. Proteinases in cutaneous wound healing. *Cell Mol Life Sci*; 66 : 203-204.

Toussaint O., Remacle J., Dierick J., Pascal T., Frippiat C., Zdanov S., Magalhaes J.P., Royer V., Chainiaux F. 2002. From the Hayflick mozaics to the mozaic of ageing. Role of stress-induces premature senescence in human ageing. *Int J BiochemCell Biol.* 34:1415-1429.

Tredget E.E., Nedelec B., Scott P.G., Ghahary A. 1997. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. *Surg Clin North Am.* 77(3): 701-730.

Tuan T. L., Zhu J. Y., Sun B., Nichter L. S., Nimni M. E., Laug W. E. 1996. Elevated levels of *plasminogen activator inhibitor-1* may account for the altered fibrinolysis by keloid fibroblasts. *J Invest Dermatol.* 106:1007-1011.

- Uchida G., Yoshimura K., Kitano Y., Okazaki M., Harii K. 2003. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts. *Exp Dermatol.* 2:35-42.
- Uitto J., Perejda A. J., Abergel R.P., Chu M.L., Ramirez F.1985. Altered steady – state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. *Proc Natl Acad Sci U. S. Am.* 82:5935-5939.
- Ulrich D., Ulrich F., Unglaub F., Platkowski A., Pallua N.2010. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. *J Plast Reconstr Aesthet Surg.* 63 :1015 – 1021.
- Viera M.H., Vivas A.C., Berman B.2012. Update on keloid management: Clinical and basic science advances. *Wound Care* (New Rochelle). 1(5):200-206.
- Wahyuningsih M.S.H., Wahyuono S.1999. Skrining toksisitas dengan BST dari daun beberapa spesies tanaman yang secara tradisional untuk mengobati tumor di Indonesia. *BIK.* 31(1):17-22.
- Wahyuningsih M.S.H., Wahyuono S., Artama W.T. 2000. Efek sitotoksik Oleandrin, senyawa bioaktif hasil isolasi dari daun *Nerium indicum* Mill. terhadap sel mieloma. *BIK.* 32(4): 23-41.
- Wahyuningsih M.S.H., Mubarika S., Ganjar I.G and Wahyuono S.,2005. Deteksi mekanisme antikanker Oleandrin hasil isolasi dari daun *Nerium indicum* Mill. terhadap sel MCF-7 menggunakan fluorescein isothiocyanate-annexin V dan gel agarose.*MOT.* 10(33):21-26.

Wahyuningsih M.S.H., Mubarika S., Bolhuis R.L.H., Nooter K., Oostrum R.G.,

Wahyuono S., Ganjar I.G. 2008. Selectivity of compounds isolated from the leaves of *N.indicum* Mill. on various human cancer cell lines.*Med J Malay.* 63: 24-25.

Wahyuningsih M.S.H., Mubarika S., Ganjar I.G and Wahyuono S., Boersma A.W.M, Nooter K. 2008. Detection of apoptosis mechanism on renal cancer cell treated by 16, 17-dehidrodeacetyl-5α-oleandrin compound isolated from *N.indicum* Mill. Leaves.*MFI.*19(4):178-184.

Wahyuningsih MSH., Mubarika S., Ganjar IG., Wahyuono S., Takeya T., 2015, Reducing BCL-2 Protein Expression and Increasing Bax Protein Expression on Hela Cell as Apoptotic Mode of 5α-oleandrin Isolated from the Leaves of *Nerium indicum* Mill., *Int J Pharm Pharm Sci.*, submission

Waki E. Y., Crumley R. L., and Jakowatz J. G.1991. Effects of pharmacologic agents on human keloids implanted in athymic mice: A pilot study. *Arch Otolaryngol Head Neck Surg.* 117: 1177-1181.

Wang Z., Gao Z., Shi Y., Sun Y., Lin Z.2007. Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. *J Plast Reconstr Aesthet Surg.* 60(11):1193-1199.

Wang X.Q., Liu Y.K., Qing C., Lu S.L. 2009. A review of the effectiveness of antimetabolic drug injections for hypertrophic scars and keloids. *Ann Plast Surg.*63(6):688-692.

Wheeland R.G.1996. *Keloid and Hypertrophic Scars*(1st ed.). Philadelphia : W.B. Saunders.

Wirohadidjojo dan Dachlan. 2007. The effect of narrow and broad band ultraviolet B onto keloid fibroblast-VEGF expressions. *Berkala Ilmu Kedokteran*. 39(2).

Wirohadidjojo Y.W., Radiono S., Budianto A., Soebono H. 2011. Cellular viability, collagen deposition, and transforming growth factor β 1 production among ultraviolet B-irradiated keloid fibroblasts. *Aesthet Plast Surg*. 35(6): 1050-1055.

Wong T.W., Chiu H.C., Chen J.S., Lin L.J., Chang C.C.1995. Symptomatic keloids in two children. Dramatic improvement with silicone cream occlusive dressing. *Arch Dermatol*. 131(7):775-777.

Viera M.H., Amini S., Valin W., Berman B. 2010. Innovative therapies in the treatment of keloids and hypertrophic scars. *J Clin Aesthet Dermatol*. 3(5):20-26.

Xia W, Phan TT, Lim IJ, Longaker MT, Yang GP. 2004. Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells. *Wound Repair Regen*; 12 : 546-556.

Yagi K. I., Dafalla A. A., Osman A. A.1979. Does an immunereaction to sebum in wounds cause keloid scars? Beneficialeffect of desensitisation. *Br J Plast Surg*. 32: 223-225.

Yang GP, Lim IJ, Phan TT, Lorenz HP, Longaker MT. 2003. From scarless fetal wounds to keloids : molecular studies in wound healing. *Wound Repair Regen*. 11 : 411-418.

Yang P., Menter D.G., Cartwright C., Chan D., Dixon S. 2009. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. *Mol Cancer Ther.* 8(8):2319-2328.

Yan-Ping R, Ming-Juan Z, Zhang, Ting Z, Ruo-Wen H. 2014. Dual effects of ouabain on the regulation of proliferation and apoptosis in human umbilical vein endothelial cells: involvement of Na⁺-K⁺-ATPase α -subunits and NF- κ B. *Int J Clin Exp Med*, 7(5):1214-1222

Yoshida K., Oshima A., Shimmoto M., Fukuhara y., Sakuraba h., Yanagisawa N., Suzuki Y.1991. Human β -Galactosidase Gene Mutations in GM1-Gangliosidosis: A common mutation among Japanese adult/chronic cases. *Am J Human Gen.* 49:435-442.

Younai S., Nichter L. S., Wellisz T., Reinisch J., Nimni M. E., Tuan T. L.1994. Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. *Ann Plast Surg.* 33:148-151.

Younai S., Venters G., Vu S., Nichter L., Nimni M. E., Tuan T. L.1996. Role of growth factors in scar contraction: An *in vitro* analysis. *Ann Plast Surg.* 36:495-501.

Yu H, Bock O, Bayat A, Ferguson MW, Mrowietz U. 2006. Decreased expression of inhibitory SMAD6 and SMAd7 in keloid scarring. *J Plast Reconstr Aesthet Surg*; 59 : 221-229.

- Zachariae H. 1988. Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. *Br J Dermatol*; 118 : 703-706.
- Zhang H. 2007. Molecular signaling and genetic pathways of snescense: It role in tumorigenesis and aging. *J Cell Physiol*. 210:567-574.
- Zhao J, Zhang N, Prestwich GD, Wen X. 2008. Recruitment of endogenous stem cells for tissue repair. *Macromol Biosci*; 8 : 836-842.
- Zhu J., Woods D., McMahon M., Bishop J.M. 1998. Senescense of human fibroblasts induced by oncogenic Raf. *Gene & Develop*. 12:2997-3007.